Compared with the trials on participants with CKD diseases (− 0.17, 95% CI: -0.43, 0.10, I2: 0.0%) or other diseases (0.10, 95% CI: -0.41, 0.60, I2: 0.0%), vitamin D consumption in clinical trials with cardiac diseases participants (− 0.57, 95% CI: -0.90, − 0.25, I2: 63.8%) significantly decreased vWF concentrations. Here, VWF is linked to heart disorder.